Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Amphastar Pharmaceuticals, Inc. stock logo
AMPH
Amphastar Pharmaceuticals
$28.31
+0.7%
$26.42
$16.65
▼
$31.00
$1.21B0.93511,473 shs333,182 shs
Calliditas Therapeutics AB (publ) stock logo
CALT
Calliditas Therapeutics AB (publ)
$40.00
$40.00
$15.25
▼
$43.00
$1.19B1.7710,339 shsN/A
Rapport Therapeutics, Inc. stock logo
RAPP
Rapport Therapeutics
$23.16
-1.8%
$30.26
$22.06
▼
$52.93
$1.37B1.4470,779 shs270,249 shs
Turn Therapeutics Inc. stock logo
TTRX
Turn Therapeutics
$8.11
-6.1%
$11.42
$2.60
▼
$16.45
$247.92MN/A70,258 shs66,852 shs
10 Best Stocks to Own in Fall 2026 Cover

AI spending is reshaping the market, and the opportunity extends far beyond the biggest chipmakers. Discover 10 stocks set to benefit from powerful trends in AI infrastructure, cloud computing, energy, capital returns, and consumer growth this fall.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Amphastar Pharmaceuticals, Inc. stock logo
AMPH
Amphastar Pharmaceuticals
-5.39%-2.63%+8.37%+30.14%+10.80%
Calliditas Therapeutics AB (publ) stock logo
CALT
Calliditas Therapeutics AB (publ)
0.00%0.00%0.00%0.00%0.00%
Rapport Therapeutics, Inc. stock logo
RAPP
Rapport Therapeutics
+0.81%-8.74%-19.68%-51.10%-12.24%
Turn Therapeutics Inc. stock logo
TTRX
Turn Therapeutics
-2.81%-14.71%-17.48%-8.67%+205.30%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Amphastar Pharmaceuticals, Inc. stock logo
AMPH
Amphastar Pharmaceuticals
$28.31
+0.7%
$26.42
$16.65
▼
$31.00
$1.21B0.93511,473 shs333,182 shs
Calliditas Therapeutics AB (publ) stock logo
CALT
Calliditas Therapeutics AB (publ)
$40.00
$40.00
$15.25
▼
$43.00
$1.19B1.7710,339 shsN/A
Rapport Therapeutics, Inc. stock logo
RAPP
Rapport Therapeutics
$23.16
-1.8%
$30.26
$22.06
▼
$52.93
$1.37B1.4470,779 shs270,249 shs
Turn Therapeutics Inc. stock logo
TTRX
Turn Therapeutics
$8.11
-6.1%
$11.42
$2.60
▼
$16.45
$247.92MN/A70,258 shs66,852 shs
10 Best Stocks to Own in Fall 2026 Cover

AI spending is reshaping the market, and the opportunity extends far beyond the biggest chipmakers. Discover 10 stocks set to benefit from powerful trends in AI infrastructure, cloud computing, energy, capital returns, and consumer growth this fall.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Amphastar Pharmaceuticals, Inc. stock logo
AMPH
Amphastar Pharmaceuticals
-5.39%-2.63%+8.37%+30.14%+10.80%
Calliditas Therapeutics AB (publ) stock logo
CALT
Calliditas Therapeutics AB (publ)
0.00%0.00%0.00%0.00%0.00%
Rapport Therapeutics, Inc. stock logo
RAPP
Rapport Therapeutics
+0.81%-8.74%-19.68%-51.10%-12.24%
Turn Therapeutics Inc. stock logo
TTRX
Turn Therapeutics
-2.81%-14.71%-17.48%-8.67%+205.30%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Amphastar Pharmaceuticals, Inc. stock logo
AMPH
Amphastar Pharmaceuticals
1.88
Reduce$23.33-17.58% Downside
Calliditas Therapeutics AB (publ) stock logo
CALT
Calliditas Therapeutics AB (publ)
0.00
N/AN/AN/A
Rapport Therapeutics, Inc. stock logo
RAPP
Rapport Therapeutics
2.93
Moderate Buy$64.50178.50% Upside
Turn Therapeutics Inc. stock logo
TTRX
Turn Therapeutics
2.67
Moderate Buy$9.0010.97% Upside

Current Analyst Ratings Breakdown

Latest TTRX, RAPP, CALT, and AMPH Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
11/16/2026
Turn Therapeutics Inc. stock logo
TTRX
Turn Therapeutics
Reiterated RatingSell (E+)
11/6/2026
Amphastar Pharmaceuticals, Inc. stock logo
AMPH
Amphastar Pharmaceuticals
Boost Price TargetEqual Weight$20.00 ➝ $25.00
11/5/2026
Rapport Therapeutics, Inc. stock logo
RAPP
Rapport Therapeutics
Lower Price TargetOverweight$50.00 ➝ $47.00
11/5/2026
Rapport Therapeutics, Inc. stock logo
RAPP
Rapport Therapeutics
Lower Price TargetBuy$71.00 ➝ $64.00
11/5/2026
Rapport Therapeutics, Inc. stock logo
RAPP
Rapport Therapeutics
Lower Price TargetBuy$70.00 ➝ $66.00
11/4/2026
Amphastar Pharmaceuticals, Inc. stock logo
AMPH
Amphastar Pharmaceuticals
UpgradeHold (C-) ➝ Hold (C)
11/4/2026
Rapport Therapeutics, Inc. stock logo
RAPP
Rapport Therapeutics
Set Price Target$73.00
10/23/2026
Turn Therapeutics Inc. stock logo
TTRX
Turn Therapeutics
UpgradeSell ➝ Hold$10.00
10/21/2026
Rapport Therapeutics, Inc. stock logo
RAPP
Rapport Therapeutics
Lower Price TargetOverweight$51.00 ➝ $50.00
10/21/2026
Rapport Therapeutics, Inc. stock logo
RAPP
Rapport Therapeutics
Boost Price TargetBuy$50.00 ➝ $82.00
10/20/2026
Rapport Therapeutics, Inc. stock logo
RAPP
Rapport Therapeutics
Reiterated RatingOutperform
(Data available from 11/20/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Amphastar Pharmaceuticals, Inc. stock logo
AMPH
Amphastar Pharmaceuticals
$745.79M1.62$4.06 per share6.98$19.10 per share1.48
Calliditas Therapeutics AB (publ) stock logo
CALT
Calliditas Therapeutics AB (publ)
$1.60B0.74N/AN/A$1.06 per share37.74
Rapport Therapeutics, Inc. stock logo
RAPP
Rapport Therapeutics
N/AN/AN/AN/A$6.60 per shareN/A
Turn Therapeutics Inc. stock logo
TTRX
Turn Therapeutics
N/AN/AN/AN/A$0.19 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Amphastar Pharmaceuticals, Inc. stock logo
AMPH
Amphastar Pharmaceuticals
$98.09M$2.1912.9310.855.2513.27%15.31%7.15%N/A
Calliditas Therapeutics AB (publ) stock logo
CALT
Calliditas Therapeutics AB (publ)
-$43.96M-$1.85N/A8.68N/A-30.18%-212.04%-27.96%N/A
Rapport Therapeutics, Inc. stock logo
RAPP
Rapport Therapeutics
-$111.48M-$3.17N/AN/AN/AN/A-34.00%-31.89%N/A
Turn Therapeutics Inc. stock logo
TTRX
Turn Therapeutics
-$3.19M-$0.43N/AN/AN/AN/A-261.87%-70.18%N/A

Latest TTRX, RAPP, CALT, and AMPH Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
11/9/2026Q3 2026
Turn Therapeutics Inc. stock logo
TTRX
Turn Therapeutics
N/A-$0.21N/A-$0.21N/AN/A
11/5/2026Q3 2026
Amphastar Pharmaceuticals, Inc. stock logo
AMPH
Amphastar Pharmaceuticals
$0.8590$1.14+$0.2810$0.87$197.52 million$207.61 million
11/4/2026Q3 2026
Rapport Therapeutics, Inc. stock logo
RAPP
Rapport Therapeutics
-$1.20-$0.84+$0.36-$0.84$0.01 millionN/A
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Amphastar Pharmaceuticals, Inc. stock logo
AMPH
Amphastar Pharmaceuticals
N/AN/AN/AN/AN/A
Calliditas Therapeutics AB (publ) stock logo
CALT
Calliditas Therapeutics AB (publ)
N/AN/AN/AN/AN/A
Rapport Therapeutics, Inc. stock logo
RAPP
Rapport Therapeutics
N/AN/AN/AN/AN/A
Turn Therapeutics Inc. stock logo
TTRX
Turn Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Amphastar Pharmaceuticals, Inc. stock logo
AMPH
Amphastar Pharmaceuticals
0.75
3.32
2.36
Calliditas Therapeutics AB (publ) stock logo
CALT
Calliditas Therapeutics AB (publ)
9.44
2.69
2.59
Rapport Therapeutics, Inc. stock logo
RAPP
Rapport Therapeutics
N/A
20.07
20.07
Turn Therapeutics Inc. stock logo
TTRX
Turn Therapeutics
1.01
3.19
3.19
CompanyEmployeesShares OutstandingFree FloatOptionable
Amphastar Pharmaceuticals, Inc. stock logo
AMPH
Amphastar Pharmaceuticals
1,97642.65 million30.03 millionOptionable
Calliditas Therapeutics AB (publ) stock logo
CALT
Calliditas Therapeutics AB (publ)
18029.79 million29.14 millionNo Data
Rapport Therapeutics, Inc. stock logo
RAPP
Rapport Therapeutics
8459.28 million51.88 millionOptionable
Turn Therapeutics Inc. stock logo
TTRX
Turn Therapeutics
230.57 million13.49 millionOptionable

Recent News About These Companies

Turn Therapeutics Inc. GAAP EPS of -$0.21
Turn Therapeutics Inc (TTRX)
Turn Therapeutics Inc.(NasdaqGM:TTRX) added to S&P TMI Index
Turn Therapeutics Inc. GAAP EPS of -$0.20

New MarketBeat Followers Over Time

Media Sentiment Over Time

Amphastar Pharmaceuticals stock logo

Amphastar Pharmaceuticals NASDAQ:AMPH

$28.31 +0.20 (+0.71%)
Closing price 03:59 PM Eastern
Extended Trading
$28.26 -0.05 (-0.17%)
As of 04:01 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency. The company provides Amphadase, an injection to absorb and disperse other injected drugs; Epinephrine injection for allergic reactions; Lidocaine jelly, an anesthetic product for urological procedures; Lidocaine topical solution for various procedures; Phytonadione injection, a vitamin K1 injection for newborn babies; emergency syringe products; morphine injection for use with patient-controlled analgesia pumps; and Lorazepam injection for surgery and medical procedures. In addition, it offers Neostigmine methylsulfate injection to treat myasthenia gravis and to reverse the effects of muscle relaxants; Isoproterenol hydrochloride injection for mild or transient episodes of heart block; Ganirelix Acetate injection for the inhibition of premature luteinizing hormone surges; Vasopressin to increase blood pressure; and Regadenoson, a stress agent for radionuclide myocardial perfusion imaging. Further, the company distributes recombinant human insulin APIs and porcine insulin API. Additionally, it develops generic product candidates, such as injectable, inhalation, and analytical technologies; biosimial product candidates; and intranasal epinephrine for the treatment of allergic reactions. The company was founded in 1996 and is headquartered in Rancho Cucamonga, California.

Calliditas Therapeutics AB (publ) stock logo

Calliditas Therapeutics AB (publ) NASDAQ:CALT

$40.00 0.00 (0.00%)
As of 11/6/2026

Calliditas Therapeutics AB (publ), a commercial-stage bio-pharmaceutical company, focused on identifying, developing, and commercializing novel treatments in orphan indications with an initial focus on renal and hepatic diseases with significant unmet medical needs in the United States, Europe, and Asia. It offers Nefecon (TARPEYO/Kinpeygo), an oral formulation of budesonide to reduce the loss of kidney function in adults with immunoglobulin A nephropathy. The company's lead compound is Setanaxib, a NOX inhibitor that is in Phase 2b clinical trial for the treatment of primary biliary cholangitis; and in Phase 2 clinical trial for the treatment of squamous cell carcinoma of the head and neck cancer and idiopathic pulmonary fibrosis, as well as for solid tumors and Alport Syndrome. Calliditas Therapeutics AB (publ) was incorporated in 2004 and is headquartered in Stockholm, Sweden.

Rapport Therapeutics stock logo

Rapport Therapeutics NASDAQ:RAPP

$23.16 -0.43 (-1.82%)
Closing price 03:58 PM Eastern
Extended Trading
$23.18 +0.02 (+0.11%)
As of 04:01 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Rapport Therapeutics Inc. is a clinical-stage biotechnology company. It focused on discovery and development of transformational small molecule medicines for patients suffering from central nervous system disorders. Rapport Therapeutics Inc. is based in BOSTON.

Turn Therapeutics stock logo

Turn Therapeutics NASDAQ:TTRX

$8.07 -0.57 (-6.54%)
As of 04:00 PM Eastern
This is a fair market value price provided by Massive. Learn more.

We are a pharmaceutical and medical device development company built around a proprietary platform technology designed to enhance drug performance. Our patented mixing process — commercially referred to as PermaFusion™ (“PermaFusion”) — enables stable suspension of polar, water-soluble active pharmaceutical ingredients (“APIs”) in oil-based carriers without the use of emulsifiers. This innovation reduces the quantity of required API inclusion by improving its bioavailability. Reduced API load reduces the likelihood of adverse events. Our proprietary platform has been validated across multiple FDA-cleared medical devices. Our primary development programs focus on dermatological diseases, including moderate to severe eczema and onychomycosis. Our company’s origin is rooted in the personal journey of our founder, who developed a topical ointment to heal his own chronic, treatment-resistant wounds using the PermaFusion platform he developed. His initial formulation, now known as Hexagen (“Hexagen”) suspends certain antimicrobial/anti-inflammatory compounds in petrolatum without known cytotoxicity, irritation or sensitization. This formula has received three FDA clearances and has been utilized extensively in humans, which we believe demonstrates both technical proof of concept and meaningful therapeutic effects. The formula also has been demonstrated to provide anti-inflammatory immunological signaling (IL 36, IL 31, IL 4 inhibition), in-vivo nail penetration with fungal pathogen elimination, and other potential therapeutic benefits. These products are not presently on the market, and we are not currently generating revenue from these devices, as we focus on drug development of our core technology. In addition to our dermatology and wound programs, we are exploring broader applications of our PermaFusion technology. In partnership with a leading global nonprofit organization, we are attempting to develop intranasal vaccines with sufficient thermostability to withstand distribution without deep-freeze. Our goal is to eliminate the need for frozen storage and, thus, enable deployment and delivery to low-resource settings that do not maintain suitable cold storage infrastructure required for administration of modern-day vaccines. Furthermore, if we are successful in this initial program, we believe there may be opportunities to develop additional vaccines in thermostable, intranasal form. By reducing cold-storage infrastructure requirements and therefore enabling standard shipping of such vaccines, we believe intranasal vaccines have the potential to enhance patient uptake by enabling immunization in a broader variety of settings including in clinic, hospital and home-health settings. We believe this initiative highlights our platform’s versatility and its potential to unlock new therapeutic categories beyond dermatology. We have also completed preclinical, in-vivo xenograft studies for herpes zoster ophthalmicus (shingles of the eye) and basal cell carcinoma. A mildly reformulated version of the Hexagen formula was employed for the ocular study and compared this reformulation with placebo as a topical ocular agent intended to reduce viral load of herpes zoster in an animal model. Results obtained showed an 85% reduction in viral load compared to placebo without adverse events. For the basal cell carcinoma xenograft study, the Hexagen formula was compared to both placebo and 5-Fluorouracil (standard of care topical chemotherapy) as a topical treatment intended to reduce basal cell tumor size. The Hexagen formula showed an approximate 29% comparative reduction in tumor size to the placebo and an approximate 20% comparative reduction in tumor size compared to 5-Fluorouracil. We believe these preclinical in-vivo studies suggest meaningful potential in these indications, which we may continue to explore at the conclusion of our lead drug programs. We believe such exploratory results further underscore the potential breadth of opportunity enabled by our platform. We were initially formed on January 6, 2015, as Global Health Solutions, LLC, a Delaware limited liability company. On October 12, 2018, Global Health Solutions, LLC converted to a Delaware corporation under the name Global Health Solutions, Inc., dba Turn Therapeutics. Immediately prior to the effectiveness of the registration statement of which this prospectus forms a part, we intend to change our name to Turn Therapeutics Inc. Our principal executive offices are located in Westlake Village, CA.